MabTrix ^{For Profit}

MabTrix is a preclinical stage biopharmaceutical company aiming to develop an innovative, function-blocking therapeutic monoclonal antibody (MAb) for inflammatory bowel disease (IBD) as the initial indication. The company’s mission is to develop a novel MAb that specifically inhibits enzymatic activity of matrix metalloprotease (MMP) 9 by binding to the catalytic site of the activated enzyme.MabTrix was established in the FutuRx incubator in December 2015.